Literature DB >> 24922495

Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis.

Jennifer M Gierisch1, Jason A Nieuwsma, Daniel W Bradford, Christine M Wilder, Monica C Mann-Wrobel, Amanda J McBroom, Vic Hasselblad, John W Williams.   

Abstract

OBJECTIVE: Individuals with serious mental illness have high rates of cardiovascular disease (CVD) risk factors and mortality. This systematic review was conducted to evaluate pharmacologic and behavioral interventions to reduce CVD risk in adults with serious mental illness. DATA SOURCES: MEDLINE, EMBASE, PsycINFO, ClinicalTrials.gov, and Cochrane Database of Systematic Reviews were searched from January 1980 to July 2012 for English language studies. Examples of search terms used include schizophrenia, bipolar disorder, antipsychotics, weight, glucose, lipid, and cardiovascular disease. STUDY SELECTION: Two reviewers independently screened citations and identified 33 randomized controlled trials of at least 2 months' duration that enrolled adults with serious mental illness and evaluated pharmacologic or behavioral interventions targeting weight, glucose, or lipid control. DATA EXTRACTION: Reviewers extracted data, assessed applicability, and evaluated study quality; the team jointly graded overall strength of evidence.
RESULTS: We included 33 studies. Most studies targeted weight control (28 studies). Compared with control groups, weight control was improved with behavioral interventions (mean difference = -3.13 kg; 95% CI, -4.21 to -2.05), metformin (mean difference = -4.13 kg; 95% CI, -6.58 to -1.68), anticonvulsive medications topiramate and zonisamide (mean difference = -5.11 kg; 95% CI, -9.48 to -0.74), and adjunctive or antipsychotic switching to aripiprazole (meta-analysis not possible). Evidence was insufficient for all other interventions and for effects on glucose and lipid control. The small number of studies precluded analyses of variability in treatment effects by patient characteristics.
CONCLUSIONS: Few studies have evaluated interventions addressing 1 or more CVD risk factors in people with serious mental illness. Glucose- and lipid-related results were mainly reported as secondary outcome assessments in studies of weight-management interventions. Comparative effectiveness studies are needed to test multimodal strategies, agents known to be effective in nonserious mental illness populations, and antipsychotic-management strategies. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24922495     DOI: 10.4088/JCP.13r08558

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  24 in total

Review 1.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

2.  Mortality and Medical Comorbidity in the Severely Mentally Ill.

Authors:  Frank Schneider; Michael Erhart; Walter Hewer; Leonie Ak Loeffler; Frank Jacobi
Journal:  Dtsch Arztebl Int       Date:  2019-06-10       Impact factor: 5.594

3.  Increasing US health plan coverage for exercise programming in community mental health settings for people with serious mental illness: a position statement from the Society of Behavior Medicine and the American College of Sports Medicine.

Authors:  Sarah I Pratt; Gerald J Jerome; Kristin L Schneider; Lynette L Craft; Matthew P Buman; Mark Stoutenberg; Gail L Daumit; Stephen J Bartels; David E Goodrich
Journal:  Transl Behav Med       Date:  2016-09       Impact factor: 3.046

Review 4.  Mental and Addictive Disorders and Medical Comorbidities.

Authors:  Elizabeth Reisinger Walker; Benjamin G Druss
Journal:  Curr Psychiatry Rep       Date:  2018-08-28       Impact factor: 5.285

5.  Improving Physical Health in Patients With Chronic Mental Disorders: Twelve-Month Results From a Randomized Controlled Collaborative Care Trial.

Authors:  Amy M Kilbourne; Michelle M Barbaresso; Zongshan Lai; Kristina M Nord; Margretta Bramlet; David E Goodrich; Edward P Post; Daniel Almirall; Mark S Bauer
Journal:  J Clin Psychiatry       Date:  2017-01       Impact factor: 4.384

6.  The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.

Authors:  Davy Vancampfort; Joseph Firth; Christoph U Correll; Marco Solmi; Dan Siskind; Marc De Hert; Rebekah Carney; Ai Koyanagi; André F Carvalho; Fiona Gaughran; Brendon Stubbs
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

7.  Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis.

Authors:  Suat Kucukgoncu; Urska Kosir; Elton Zhou; Erin Sullivan; Vinod H Srihari; Cenk Tek
Journal:  Early Interv Psychiatry       Date:  2018-10-02       Impact factor: 2.732

Review 8.  Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.

Authors:  Emma E McGinty; Julia Baller; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

9.  Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.

Authors:  Davy Vancampfort; Brendon Stubbs; Alex J Mitchell; Marc De Hert; Martien Wampers; Philip B Ward; Simon Rosenbaum; Christoph U Correll
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

10.  Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.

Authors:  Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs
Journal:  World Psychiatry       Date:  2016-06       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.